Do you need what you need?These 343 kinds of medicines need to enter medical insurance!Including a number of rare medicines

From September 6th to 12th, the National Medical Security Bureau announced the list of application drugs that passed the preliminary form review of the National Medical Insurance Drug Catalog in 2022. Recently, according to the feedback from all parties, the drugs were reviewed and revised according to procedures. On September 17, the State Medical Insurance Bureau officially announced the "List of Application Drugs, Catalogs for Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogs in 2022. A total of 343 drugs were officially passed for review (detailed poke view → list). Essence

In 2022, a total of 343 kinds of drugs passed the form of the national medical insurance, work injury insurance and maternity insurance drug directory adjustment through formal review. Western medicine and Chinese medicines and Ada Mibu anti -injection in 145 types of western medicines and Chinese medicines, compared with 344 drugs on the list of drug lists that have been reviewed by preliminary forms, reduced 1 kind of western medicine -methane psychiatric swin -ginseng bloating thrombosis Essence

In the context of the normalization of the new coronary pneumonia epidemic, starting from the first implementation of the medical insurance drug directory enterprise independently declared system in 2020, the State Medical Insurance Administration attaches great importance to the treatment of new crown pneumonia. "Pharmaceutical" "Pharmaceuticals" as one of the application conditions, a number of new crown treatment medications have been included in the medical insurance drug catalog. The National Medical Insurance Administration stated that during the application process, the new crown pneumonia therapy drugs that have been declared and reviewed through formal review will carry out follow -up work in accordance with procedures and strive to officially include the medical insurance directory at a reasonable price.

In July, the National Medical Insurance Bureau stated that there was no time limit for the launch of the medical insurance directory for the "approved listing after January 1, 2017" for rare diseased drugs. As early as this year, when the medical insurance directory negotiation work was launched, the State Medical Insurance Bureau made it clear that the medical insurance directory would appropriately tilt to special groups such as patients with rare diseases and children. The list of drugs that passed the formal review contains a number of rare diseases, such as spinal muscle atrophy (SMA) therapeutic pharmaceutical Liste Polan oral solution, type Ⅰ Gobei disease treatment drug injection for hemididin, hemidin, Ease enzymes, type Ⅰ adhesive polysaccharides, special effects of adhesive and accumulation of Roninase, adurtlase enzyme enzyme α, etc.

The National Medical Insurance Bureau stated that the adjustment of medical insurance and drug catalogs is divided into aspects of corporate application, form review, expert review, negotiating bidding, etc. The formal review is only one of them. Through form review, the drug is eligible to enter the next expert review session. Only by successfully adjusting the directory adjustment can it be eventually included in the national medical insurance directory.

In the next step, the National Medical Insurance Administration will organize the work of expert review in accordance with the requirements of the "Interim Measures for the Management of Basic Medical Insurance Drugs" and "2022 National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog". If the progress is smooth, the new version of the medical insurance drug catalog will be announced in November, and the implementation of the landing on January 1 next year will be announced.

Source: Beijing Daily

PSAs

- END -